 |
市场调查报告书
商品编码
1373891
全球肾臟生物标记市场规模、份额和增长分析：按类型和最终用户 - 行业预测（2023-2030）Global Renal Biomakers Market Size, Share, Growth Analysis, By Type(Functional biomarkers, up-regulated proteins), By End-user(Hospitals, diagnostic laboratories) - Industry Forecast 2023-2030 |
||||||
2021年全球肾臟生物标记市场规模为11.2亿美元，从2022年的12亿美元增加到2030年的21.6亿美元，年复合成长率预计将成长7.6%。
由于对肾臟疾病的高效诊断工具和个体化治疗方法的需求不断增长，该市场正在呈现显着增长。市场成长是由多种因素驱动的。首先，全球肾臟疾病盛行率的不断上升推动了对准确、可靠的诊断工具的需求。由于高龄化、糖尿病和高血压负担的增加以及生活方式相关因素等因素，慢性肾臟病尤其显着。及时诊断和管理肾臟疾病的需要导致临床实践中越来越多地采用肾臟生物标记。此外，技术进步和创新生物标记检测技术的发展提高了肾臟生物标记检测的敏感度、特异性和准确性。这些进步使医疗保健专业人员能够做出更资讯的治疗决策并有效监测肾臟疾病的进展。此外，对个人化医疗和标靶治疗的重视增加了对可以预测治疗反应并指导选择适当治疗性介入的生物标记的需求。
全球肾臟生物标记市场动态
全球肾臟生物标记市场的驱动因素
肾臟疾病盛行率增加
慢性肾臟病（CKD）、肾衰竭和急性肾损伤（AKI）等肾臟疾病的发生率和盛行率不断增加，推动了对肾臟生物标记的需求。这些生物标记在肾臟疾病的早期检测、准确诊断和监测中发挥重要作用，从而能够及时干预并改善患者的预后。
诊断技术的进步
蛋白质体学、基因组学和代谢组学等诊断技术的进步扩大了可用肾臟生物标记的范围。这些技术提高了检测肾功能障碍和评估疾病进展的敏感性、特异性和准确性。将这些技术与传统诊断方法整合进一步增加了对肾臟生物标记的需求。
全球肾臟生物标记市场的抑制因素
法规挑战
生物标誌物的法规形势复杂且不断变化。获得法规的核准并满足严格的品质和安全标准需要时间和资源。与生物标誌物开发和商业化相关的法规挑战可能会阻碍市场成长和创新。
认识和采用有限
儘管肾臟生物标记具有潜在的好处，但医疗保健专业人员和患者对生物标记在肾臟疾病管理中的效用的认识仍然有限。缺乏对肾臟生物标记的效用和益处的教育和认识可能会阻碍普及和利用。
全球肾臟生物标记的趋势
越来越多地采用个人化医疗：肾臟生物标记领域的个人化医疗呈现成长趋势。医疗保健提供者越来越多地利用生物标记根据患者个体特征和疾病进展制定治疗计划。这种方法可以实现更有针对性和更有效的治疗，进而改善患者的治疗效果。
生物标记发现技术的进步：生物标记发现领域取得了重大进展，特别是在基因组学、蛋白质组学和代谢组学领域。这些技术的进步将能够识别与肾臟疾病相关的新的、更特异性的生物标记。组学技术与先进分析和机器学习技术的整合进一步增强了生物标记发现的能力。
本报告研究和分析了全球肾臟生物标记市场，提供市场动态和前景、細項分析、公司简介等。
目录
执行摘要
调查方法
母市场分析
主要市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 智慧财产权分析
- 贸易分析
- 启动分析
- 原料分析
- 创新矩阵
- 研发线产品分析
- 总体经济指标
- 主要投资分析
- 关键成功因素
- 竞争程度
市场动态及展望
- 市场动态
- 促进因素
- 机会
- 抑制因素
- 任务
- 法规形势
- 波特的分析
- 对未来中断的特殊考察
全球肾臟生物标记市场：按类型
- 市场概况
- 功能性生物标记
- 上调蛋白质
- 其他生物标记类型
全球肾臟生物标记市场：依最终用户分类
- 市场概况
- 医院
- 诊断实验室
- 其他最终用户
全球肾臟生物标记市场规模：按地区划分
- 市场概况
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲
- 中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲
竞争形势
- 前5名企业对比
- 主要企业市场定位（2021年）
- 主要市场参与者所采取的策略
- 关键成功策略
- 近期市集活动
- 主要企业市场占有率（2021年）
主要企业简介
- Siemens Healthineers - Germany
- Roche Diagnostics - Switzerland
- Abbott Laboratories - US
- Thermo Fisher Scientific Inc. - US
- Beckman Coulter, Inc. (Danaher Corporation) - US
- bioMerieux SA - France
- Randox Laboratories Ltd. - UK
- Ortho Clinical Diagnostics - US
- Fujirebio Inc. (Miraca Holdings Inc.) - Japan
- Bio-Rad Laboratories, Inc. - US
- Nova Biomedical Corporation - US
- Ortho Clinical Diagnostics - US
- Quest Diagnostics Incorporated - US
- Sysmex Corporation - Japan
- ACON Laboratories, Inc. - US
- Gold Standard Diagnostics Corp. - US
- R&D Systems, Inc. (Bio-Techne Corporation) - US
- Dako (Agilent Technologies, Inc.) - US
- DiaSorin SpA - Italy
- Tosoh Corporation - Japan
Global Renal Biomakers Market size was valued at USD 1.12 billion in 2021 and is poised to grow from USD 1.2 billion in 2022 to USD 2.16 billion by 2030, at a CAGR of 7.6% during the forecast period (2023-2030).
The global renal biomarkers market is experiencing significant growth as the demand for efficient diagnostic tools and personalized treatment approaches for renal diseases continues to rise. Renal biomarkers are specific indicators or substances that provide valuable information about kidney function, injury, or disease progression. These biomarkers play a crucial role in the early detection, diagnosis, and monitoring of various renal conditions, such as chronic kidney disease, acute kidney injury, and renal transplantation. The growth of the global market is driven by several factors. Firstly, the increasing prevalence of renal diseases worldwide is fueling the demand for accurate and reliable diagnostic tools. Chronic kidney disease, in particular, has witnessed a significant rise due to factors such as aging populations, the growing burden of diabetes and hypertension, and lifestyle-related factors. The need for timely diagnosis and management of renal diseases has led to the adoption of renal biomarkers in clinical settings. Moreover, advancements in technology and the development of innovative biomarker detection techniques have improved the sensitivity, specificity, and accuracy of renal biomarker tests. These advancements enable healthcare professionals to make more informed treatment decisions and monitor the progression of renal diseases effectively. Additionally, the emphasis on personalized medicine and targeted therapies is driving the demand for biomarkers that can predict treatment response and guide the selection of appropriate therapeutic interventions.
Top-down and bottom-up approaches were used to estimate and validate the size of the global Renal Biomakers Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Renal Biomakers Market Segmental Analysis
Global Renal Biomakers Market is segmented on the basis of type, end-user, and region. By type, the market is segmented into functional biomarkers, up-regulated proteins, and other biomarker types. By end user, the market is segmented into hospitals, diagnostic laboratories, and other end users. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Renal Biomakers Market Dynamics
Drivers of the Global Renal Biomakers Market
Increasing Prevalence of Renal Diseases
The growing incidence and prevalence of renal diseases, including chronic kidney disease (CKD), kidney failure, and acute kidney injury (AKI), are driving the demand for renal biomarkers. These biomarkers play a crucial role in early detection, accurate diagnosis, and monitoring of renal diseases, thereby enabling timely intervention and improved patient outcomes.
Technological Advancements in Diagnostic Technologies
The advancements in diagnostic technologies, such as proteomics, genomics, and metabolomics, have expanded the range of available renal biomarkers. These technologies offer enhanced sensitivity, specificity, and accuracy in detecting renal dysfunction and evaluating disease progression. The integration of these technologies with traditional diagnostic methods has further fueled the demand for renal biomarkers.
Restraints in the Global Renal Biomakers Market
Regulatory Challenges
The regulatory landscape for biomarkers is complex and constantly evolving. Obtaining regulatory approvals and meeting stringent quality and safety standards can be time-consuming and resource-intensive. The regulatory challenges associated with biomarker development and commercialization can hinder market growth and innovation.
Limited Awareness and Adoption
Despite the potential benefits of renal biomarkers, there is still limited awareness among healthcare professionals and patients about their utility in renal disease management. Lack of education and awareness about the availability and benefits of renal biomarkers may hinder their widespread adoption and utilization in clinical practice.
Market Trends of Global Renal Biomakers Key
Increasing Adoption of Personalized Medicine: There is a growing trend towards personalized medicine in the field of renal biomarkers. Healthcare providers are increasingly utilizing biomarkers to tailor treatment plans based on individual patient characteristics and disease progression. This approach enables more targeted and effective therapies, leading to improved patient outcomes.
Advancements in Biomarker Discovery Techniques: The field of biomarker discovery is witnessing significant advancements, particularly in the areas of genomics, proteomics, and metabolomics. These technological advancements allow for the identification of novel and more specific biomarkers associated with renal diseases. The integration of omics technologies with advanced analytics and machine learning techniques is further enhancing biomarker discovery capabilities.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Renal Biomakers Market by Type
- Market Overview
- Functional biomarkers
- up-regulated proteins
- and other biomarker types
- Global Renal Biomakers Market by End-user
- Market Overview
- Hospitals
- diagnostic laboratories
- and other end users
- Global Renal Biomakers Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Siemens Healthineers - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Diagnostics - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beckman Coulter, Inc. (Danaher Corporation) - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- bioMerieux SA - France
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Randox Laboratories Ltd. - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ortho Clinical Diagnostics - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujirebio Inc. (Miraca Holdings Inc.) - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nova Biomedical Corporation - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ortho Clinical Diagnostics - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quest Diagnostics Incorporated - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ACON Laboratories, Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gold Standard Diagnostics Corp. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- R&D Systems, Inc. (Bio-Techne Corporation) - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dako (Agilent Technologies, Inc.) - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DiaSorin S.p.A. - Italy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tosoh Corporation - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
